Drug Profile
DX 0308
Alternative Names: DX-0308; DX308Latest Information Update: 28 May 2023
Price :
$50
*
At a glance
- Originator DermaXon
- Class Antiparkinsonians; Neuroprotectants; Skin disorder therapies
- Mechanism of Action Retinoic acid metabolism modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Ichthyosis; Parkinson's disease
Most Recent Events
- 28 May 2023 No recent reports of development identified for preclinical development in Ichthyosis in USA
- 28 May 2023 No recent reports of development identified for preclinical development in Parkinson's-disease in USA
- 06 May 2021 DX 0308 is still in preclinical development for Parkinson's disease in USA (unspecified route) (DermaXon pipeline, May 2021)